新型冠状病毒感染对异基因造血干细胞移植移植物组分及早期移植结局的影响
本研究纳入2022年12月8日至2023年1月10日接受allo-HSCT的71例恶性血液病患者,比较轻症COVID-19供者(16例)与未感染供者(55例)的移植物组分及早期结局。两组植入率与植入时间无显著差异,D-COVID(+)组NK细胞剂量较高,aGVHD累积发生率差异无统计学意义。结论认为在无替代供者且移植无法推迟或中止时,如供者可耐受,可考虑使用轻症COVID-19供者。
要点
- 轻症COVID-19供者移植物MNC和CD34+细胞计数与未感染供者相当,无需更多采集次数。
- D-COVID(+)组中位NK细胞剂量0.69×10^8/kg,高于D-COVID(-)组0.53×10^8/kg(P=0.031)。
- 两组60天血小板植入率、粒细胞和血小板植入时间、60天OS及aGVHD累积发生率均无显著差异。
核心结论
- 在无替代供者且allo-HSCT无法推迟或中止时,如供者可耐受,可考虑使用轻型COVID-19供者按原计划进行移植。
- 需要更大样本量和更长随访时间验证上述结果。
研究设计与样本
- 纳入2022年12月8日至2023年1月10日接受allo-HSCT的恶性血液病患者71例,其中D-COVID(+)组16例接受轻症COVID-19供者移植物,D-COVID(-)组55例接受未感染供者移植物。
- 比较两组移植物组分,观察早期植入、aGVHD、总生存和复发等结局。
主要发现
- D-COVID(+)组供者未发生严重不良事件。
- 两组MNC和CD34+细胞计数相当,无需更多采集次数;淋巴细胞、单核细胞、T细胞亚群分布差异无统计学意义。
- D-COVID(+)组移植物中位NK细胞含量0.69×10^8/kg vs D-COVID(-)组0.53×10^8/kg(P=0.031)。
- 中位随访72(33~104)d,所有患者均获得粒细胞植入;60 d血小板植入率D-COVID(+)组100% vs D-COVID(-)组(96.4±0.2)%(P=0.568),粒细胞和血小板植入时间差异均无统计学意义(P=0.309,P=0.544)。
- Ⅱ~Ⅳ度aGVHD累积发生率D-COVID(+)组(37.5±1.6)% vs D-COVID(-)组(16.4±0.3)%(P=0.062),Ⅲ/Ⅳ度aGVHD累积发生率(25.0±1.3)% vs (9.1±0.2)%(P=0.095),60 d总生存率100% vs (98.1±1.8)%(P=0.522),随访期间未发生原发病复发。
临床怎么用
- 作者认为,在无替代供者且allo-HSCT无法推迟或中止时,如供者可耐受,可考虑使用轻型COVID-19供者按原计划进行移植。
局限性
- 需要更大样本量和更长随访时间验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To assess the feasibility of using donors with novel coronavirus disease 2019 (COVID-19) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) when there are no other available donors and allo-HSCT cannot be delayed or discontinued. Methods: Seventy-one patients with malignant hematological diseases undergoing allo-HSCT between December 8, 2022, and January 10, 2023, were included. Of these, 16 received grafts from donors with mild COVID-19 (D-COVID(+) group) and 55 received grafts from donors without COVID-19 (D-COVID(-) group). The graft compositions were compared between the two groups. Engraftment, acute graft-versus-host disease (aGVHD), overall survival (OS), and relapse were also evaluated. Results: There were no serious side effects or adverse events in the D-COVID(+) group. The mononuclear cell dose and CD34(+) cell dose were comparable between the two groups, and no additional apheresis was required. There were no significant differences in the lymphocyte, monocyte, and T-cell subset doses between the two groups. The median natural killer cell dose in the D-COVID(+) group was significantly higher than that in the D-COVID(-) group (0.69×10(8)/kg vs. 0.53×10(8)/kg, P=0.031). The median follow-up time was 72 (33-104) days. All patients achieved primary engraftment. The 60-day platelet engraftment rates in the D-COVID(+) and D-COVID(-) groups were 100% and (96.4±0.2) %, respectively (P=0.568). There were no significant differences in neutrophil (P=0.309) and platelet (P=0.544) engraftment times. The cumulative incidence of grade 2-4 aGVHD was (37.5±1.6) % vs. (16.4±0.3) % (P=0.062), and of grade 3-4 aGVHD was 25.0% ±1.3% vs. 9.1% ±0.2% (P=0.095) in the D-COVID(+) and D-COVID(-) groups, respectively. The probabilities of 60-day OS were 100% and 98.1% ±1.8% (P=0.522) in the D-COVID(+) and D-COVID(-) groups, respectively. There was no relapse of primary disease during the study period. Conclusion: When allo-HSCT cannot be delayed or discontinued and no other donor is available, a donor with mild COVID-19 should be considered if tolerable. Larger sample sizes and longer follow-up periods are required to validate these results. 目的: 评估供者发生新型冠状病毒感染(COVID-19)时,在没有其他可用供者且异基因造血干细胞移植(allo-HSCT)无法推迟或中止的情况下,使用原计划供者进行allo-HSCT的可行性。 方法: 纳入71例在2022年12月8日至2023年1月10日接受allo-HSCT的恶性血液病患者,其中16例接受轻症新冠病毒感染供者移植物(D-COVID(+)组),55例接受未感染新冠病毒感染供者移植物(D-COVID(-)组)。比较D-COVID(+)组和D-COVID(-)组供者采集物组分,观察两组早期植入、急性移植物抗宿主病(aGVHD)、总生存和复发等结局。 结果: D-COVID(+)组供者未发生严重不良事件。与D-COVID(-)组相比,D-COVID(+)组移植物的单个核细胞(MNC)和CD34(+)细胞计数相当,且无需更多的采集次数。两组淋巴细胞、单核细胞、T细胞亚群分布差异无统计学意义,而D-COVID(+)组移植物中位NK细胞含量高于D-COVID(-)组(0.69×10(8)/kg对0.53×10(8)/kg,P=0.031)。中位随访时间为72(33~104)d。所有患者均获得粒细胞植入。D-COVID(+)组、D-COVID(-)组移植后60 d血小板植入率分别为100%、(96.4±0.2)%(P=0.568),并且粒细胞植入、血小板植入时间差异均无统计学意义(P=0.309,P=0.544)。D-COVID(+)组、D-COVID(-)组Ⅱ~Ⅳ度aGVHD累积发生率分别为(37.5±1.6)%、(16.4±0.3)%(P=0.062),Ⅲ/Ⅳ度aGVHD累积发生率分别为(25.0±1.3)%、(9.1±0.2)%(P=0.095),移植后60 d总生存率分别为100%、(98.1 ± 1.8)%(P=0.522)。随访期间未发生原发病复发。 结论: 在无替代供者且allo-HSCT无法推迟或中止时,如供者可耐受,可考虑使用轻型新型冠状病毒感染供者按原计划进行移植。.
引用
- Lin F, Sun H, Chen Y, et al. [Impact of SARS-CoV-2 infection on graft composition and early transplant outcomes following allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 38185517. doi:10.3760/cma.j.issn.0253-2727.2023.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。